What is A Plus Biotechnology Co., Ltd.'s (6918.TW) StockRank?

MoatMap's StockRank for A Plus Biotechnology Co., Ltd. (6918.TW) is 74/100, with a Buy signal. This is a composite score combining Quality (70), Value (61), and Momentum (31) factor ranks across MoatMap's 20,000+ stock universe.

Does A Plus Biotechnology Co., Ltd. have an economic moat?

A Plus Biotechnology Co., Ltd. (6918.TW) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is A Plus Biotechnology Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for A Plus Biotechnology Co., Ltd. (6918.TW) is Buy, based on a StockRank of 74/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is A Plus Biotechnology Co., Ltd. in?

A Plus Biotechnology Co., Ltd. (6918.TW) operates in the Healthcare sector, specifically the Medical Devices industry (Taiwan).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

6918.TW

BUYREMOVE

A Plus Biotechnology Co., Ltd. · Healthcare · Taiwan · $80M · Avg Vol: $96K/d

StockRank

P/E (TTM)

14.4x

ROE

17.5%

D/E

0.1x

Dividend %

6.8%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

A Taiwanese medical device company with decent quality metrics but lacking the scale, pricing power, or direct macro theme connection required for high conviction.

COMPANY DESCRIPTION

A Plus Biotechnology Co., Ltd. designs, develops, and manufactures orthopedic medical devices, with a primary focus on spinal implants and trauma fixation systems. The company leverages its proprietary manufacturing technologies and regulatory clearances to compete effectively in both domestic and international healthcare markets. It operates as a high-growth niche player, benefiting from aging demographics and increasing demand for minimally invasive surgical solutions.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	19.4M	21.3M	24.3M	26.4M	10.7%
EPS	0.04	0.05	-0.01	0.16	—	63.1%
Shares	—	30.5M	30.5M	30.5M	34.6M	+13.5%
Debt	—	4.4M	3.6M	3.4M	3.0M	-11.6%
Equity	—	27.7M	26.2M	29.0M	39.9M	12.9%
Op CF	—	1.9M	5.0M	5.1M	5.0M	37.9%
Inv CF	—	-1.0M	-0.2M	-1.2M	-2.3M	—
Fin CF	—	-3.1M	-2.2M	-2.5M	5.0M	—

PRICE (1Y)-4.8%

SMA 50SMA 200

$2.32

RSI (14)

46.4

52W High

$4.01

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

16.1%87.1

ROE

17.5%86.4

GP/Assets

37.5%76.4

Op. Margin

24.1%87.6

FCF/Assets

2.4%59.3

Piotroski

430.3

Int. Cover

50.0x88.4

D/E Ratio

0.14x59.9

Current Ratio

3.16x55.7

Value

P/E (TTM)

14.4x74.3

EV/EBITDA

9.1x72.1

P/FCF

2172.3x15.2

P/B

2.2x55.5

P/S

2.9x57.1

Div Yield

6.8%96.5

Momentum

52W High %

58%36.0

RS 6M

-75%13.0

SMA 50/200

0.93x42.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

9%50.4

FUNDAMENTALS

Market Cap

$80M

P/E (Forward)

—

Gross Margin

67.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 6918.TW are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
6918.TW	A Plus Biotechnology Co., Ltd.(you)	$80M	74	BUY
4155.TW	OK Biotech Co., Ltd.	$67M	66	BUY
4106.TW	Wellell Inc.	$74M	91	STRONG BUY
4129.TWO	United Orthopedic Corporation	$275M	64	HOLD
6861.TW	InnoCare Optoelectronics Corporation	$497M	72	BUY
4736.TW	TaiDoc Technology Corporation	$368M	91	STRONG BUY
6796.TW	Medimaging Integrated Solution Inc.	$75M	12	STRONG SELL
6934.TW	HCMED INNOVATIONS CO LTD	$78M	4	STRONG SELL
1762.TW	Chunghwa Chemical Synthesis & Biotech Co., Ltd.	$87M	76	BUY
9103.TW	Medtecs International Corporation Limited	$90M	65	BUY

Peer medians: ROE 3.4% · P/E 16.4x · Gross margin 42.1%

A Plus Biotechnology Co., Ltd. (6918.TW) — Stock Score Summary

A Plus Biotechnology Co., Ltd. (6918.TW) has a MoatMap StockRank of 74/100 based on Quality (70/100), Value (61/100), and Momentum (31/100) factor scores. The current signal is BUY. A Taiwanese medical device company with decent quality metrics but lacking the scale, pricing power, or direct macro theme connection required for high conviction.

Key Financial Metrics

Price	$2.32
Market Cap	$80M
P/E (TTM)	14.37
Price/Book	2.22
Return on Equity	17.5%
Return on Invested Capital	16.1%
Debt/Equity	14.28
Gross Margin	67.3%
Operating Margin	24.1%
Revenue Growth	11.7%
Dividend Yield	6.8%
Free Cash Flow	$37K

A Plus Biotechnology Co., Ltd. operates in the Medical Devices industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is A Plus Biotechnology Co., Ltd.’s (6918.TW) StockRank?: MoatMap’s StockRank for A Plus Biotechnology Co., Ltd. (6918.TW) is 74/100, with a Buy signal. It is a composite of Quality (70), Value (61), and Momentum (31) factor ranks across MoatMap’s 20,000+ stock universe.
Does A Plus Biotechnology Co., Ltd. have an economic moat?: A Plus Biotechnology Co., Ltd. (6918.TW) has a Quality factor score of 70/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is A Plus Biotechnology Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for A Plus Biotechnology Co., Ltd. (6918.TW) is Buy, based on a StockRank of 74/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is A Plus Biotechnology Co., Ltd. in?: A Plus Biotechnology Co., Ltd. (6918.TW) operates in the Healthcare sector, specifically the Medical Devices industry (Taiwan).